SCREENER CHART SD50 CALENDAR NEWS

...

Pasithea Therapeutics Corp. (KTTA) Stock · BUY · RECOVERY | LOPJLB

Pasithea Therapeutics Corp. (KTTA)

Healthcare · Biotechnology · NASDAQ · US

$0.51-5.56%Close

BUYRECOVERY · day 15

KTTA▲ BUY

$0.51-5.56%

Overview FinancialsFin EarningsEarn Analyst & RatingsAnalyst News Holders & ETFsHold Options

Key stats

Short interest · FINRA settlement 2026-07-31

Market cap: $4M
Avg volume: 660.4K
Beta: 0.29
P/E (TTM): -0.27

Short % float: 2.69%
Days to cover: 1.0
SI change: -19.1%

1W: +6.25%
1M: +10.87%
3M: -27.14%
YTD: -57.14%

vs SPY 1W: +7.44%
vs SPY 1M: +7.55%
vs SPY 3M: -29.53%
vs SPY YTD: -68.90%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics…

Employees: 5
Headquarters: US
Founded: 2021
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 7.4M
Float: 98.4%

pasithea.com ↗

Key executives

Tiago Reis Marques — Chief Executive Officer & Director

Daniel H. Schneiderman — Chief Financial Officer

Lawrence Steinman — Co-Founder & Executive Chairman

SEC filings

EDGAR · CIK 18413300 · KTTA

All filings
10-K
10-Q
8-K
Form 4

Analyst consensus

Buy

Bullish2100.0%

Neutral00.0%

Bearish00.0%

L $3.00Avg $3.00H $3.00

Target$3.00+488.24%

Last$0.51

Company news

defenseworld.net · 13d ago

Reviewing Oncobiologics (NASDAQ:OTLK) and Pasithea Therapeutics (NASDAQ:KTTA)

globenewswire.com · 35d ago

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026

zacks.com · 36d ago

New Strong Buy Stocks for July 20th

globenewswire.com · 48d ago

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

globenewswire.com · 56d ago

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

globenewswire.com · 70d ago

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

globenewswire.com · 71d ago

Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference

zacks.com · 76d ago

Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

globenewswire.com · 84d ago

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Market news & ticker search · RSS for KTTA

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart SD50 News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Track Record Editorial Plays Feeling Lucky Blog Changelog Docs

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCPENT·Developers

© 2026 LOPJLB Research. All rights reserved.

@lopjlb contact@lopjlb.com

RANGE

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONEREGIMERECOVERYCRISIS